ConductScience.org, home

Paper20041482

Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Bishop MR and 8 others. Cancer, 2010. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Papers, record 20041482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20041482

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
PubMed
Journal
Cancer
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.22
iCite
Revised in PubMed
2025-05-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bishop MRMichael R
2Dean RMRobert M
3Steinberg SMSeth M
4Odom JJeanne
5Pollack SMSeth M
6Pavletic SZSteven Z
7Sportes CClaude
8Gress RERonald E
9Fowler DHDaniel H

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematopoietic Stem Cell TransplantationMajor topic
Lymphoma, Non-HodgkinMajor topic
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Cyclophosphamide
Disease-Free Survival
Doxorubicin
Etoposide
Female
Humans
Male
Middle Aged
Postoperative Period
Prednisone
Preoperative Period
Survival Rate
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Vincristine

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z01 BC010254Intramural NIH HHSUnited StatesZ01BC010254PubMedNIH RePORTER
Z99 CA999999Intramural NIH HHSUnited StatesZ99CA999999PubMedNIH RePORTER
ZIABC010698NIHNIH RePORTER
ZIABC011239NIHNIH RePORTER
ZIASC010288NIHNIH RePORTER
ZIASC010365NIHNIH RePORTER
ZIDBC010963NIHNIH RePORTER
ZIDSC007202NIHNIH RePORTER

Download CSV of grants

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112963698The graft-versus-lymphoma effect: fact, fiction, or opportunity?J Clin Oncol2003https://conductscience.org/library/papers/12963698PubMed
21991174Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.Blood1991https://conductscience.org/library/papers/1991174PubMed
312393626
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Blood2002https://conductscience.org/library/papers/12393626PubMed
45910392Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother Rep1966https://conductscience.org/library/papers/5910392PubMed
512963703
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
J Clin Oncol2003https://conductscience.org/library/papers/12963703PubMed
615304395Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.Blood2004https://conductscience.org/library/papers/15304395PubMed
715197204Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.J Clin Oncol2004https://conductscience.org/library/papers/15197204PubMed
87687667EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.J Clin Oncol1993https://conductscience.org/library/papers/7687667PubMed
917488686
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Haematologica2007https://conductscience.org/library/papers/17488686PubMed
1016211312Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review).Oncol Rep2005https://conductscience.org/library/papers/16211312PubMed
118049425Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.Blood1994https://conductscience.org/library/papers/8049425PubMed
1212446434Non-myeloablative transplantation.Hematology Am Soc Hematol Educ Program2002https://conductscience.org/library/papers/12446434PubMed
139807740Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.J Immunother1998https://conductscience.org/library/papers/9807740PubMed
1414645431Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.J Clin Oncol2003https://conductscience.org/library/papers/14645431PubMed
153899355Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials.Cancer Treat Rep1985https://conductscience.org/library/papers/3899355PubMed
163319146Passive, adoptive, and active immunotherapy: a review of clinical trials in cancer.Cancer Detect Prev Suppl1987https://conductscience.org/library/papers/3319146PubMed
1716269861Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.Acta Haematol2005https://conductscience.org/library/papers/16269861PubMed
1812692607
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Bone Marrow Transplant2003https://conductscience.org/library/papers/12692607PubMed
1910204198Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.Stat Med1999https://conductscience.org/library/papers/10204198PubMed
2018086796
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
J Clin Oncol2008https://conductscience.org/library/papers/18086796PubMed

See all 48 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
39513887High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role?Cells2024https://conductscience.org/library/papers/39513887PubMed
30826465Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/30826465PubMed
25228589Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Oncotarget2014https://conductscience.org/library/papers/25228589PubMed
25054045Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.Mol Clin Oncol2014https://conductscience.org/library/papers/25054045PubMed
24055823Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Blood2013https://conductscience.org/library/papers/24055823PubMed
23006952Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma.Cancer J2012https://conductscience.org/library/papers/23006952PubMed
22312100Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.J Clin Oncol2012https://conductscience.org/library/papers/22312100PubMed
21946246Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Curr Opin Oncol2011https://conductscience.org/library/papers/21946246PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20041482

GET https://conductscience.org/api/papers/v1/20041482/references?page=2